Travere Company Profile

What is the competitive landscape for TRAVERE

TRAVERE has one approved drug.

There are two US patents protecting TRAVERE drugs.

There are twenty-nine patent family members on TRAVERE drugs in nineteen countries and twelve supplementary protection certificates in twelve countries.

Summary for Travere

International Patents:	29
US Patents:	2
Tradenames:	1
Ingredients:	1
NDAs:	1

Drugs and US Patents for Travere

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No	9,993,461
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No	9,662,312
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes	9,662,312

International Patents for Travere Drugs

Country	Patent Number	Estimated Expiration
Hong Kong	1244687
European Patent Office	3708163
European Patent Office	3708163
Croatia	P20171197
Hungary	E033494
Spain	2811342

Supplementary Protection Certificates for Travere Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3222277	PA2024527	Lithuania		PRODUCT NAME: SPARSENTANAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1788 20240419
3222277	24C1038	France		PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1788 20240423
3222277	2024C/537	Belgium		PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1788 20240423
3222277	301291	Netherlands		PRODUCT NAME: SPARSENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: NOT AVAILABLE
3222277	CA 2024 00036	Denmark		PRODUCT NAME: SPARSENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1788 20240423
3222277	C202430038	Spain		PRODUCT NAME: ESPARSENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1788; DATE OF AUTHORISATION: 20240419; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1788; DATE OF FIRST AUTHORISATION IN EEA: 20240419

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Travere

Pharmaceutical Competitive Landscape Analysis: Travere – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What Is Travere's Current Market Position?

Travere Therapeutics ranks as a mid-sized, specialized biotech company focusing on rare and severe diseases. It reported revenues of approximately $340 million in 2022, primarily driven by its flagship product, Filspari (sparsentan), indicated for treating IgA nephropathy and stage 3 or 4 chronic kidney disease (CKD). The company's valuation, as of Q4 2022, stood around $2.6 billion, reflecting investor confidence in its rare disease pipeline.

The company holds a competitive edge in nephrology and rare diseases, with a strategic emphasis on unmet medical needs. Its patent portfolio includes key compositions and methods of use, extending exclusivity until 2035 in some instances.

Who Are Travere's Main Competitors?

Travere competes mainly with the following companies:

Company	Focus Area	Revenue (2022)	Key Products	Market Cap (2022)
Genentech (Roche)	Nephrology, autoimmune, oncology	$78B	Rituximab, Opdivo	$221B
Retrophin** (Now part of Travere)	Rare diseases, nephrology	$124M	Thiola (tiopronin), Chenodal	N/A (merged)
Calliditas Therapeutics	Kidney diseases, renal fibrosis	$224M	Nefecon (for IgA nephropathy)	$2.4B
Kiniksa Pharmaceuticals	Autoimmune, inflammatory diseases	$122M	Rilzabrutinib (clinical trials)	$0.3B

Note: Retrophin is now fully integrated into Travere post-acquisition.

What Are Travere's Strengths?

Focus on Rare Diseases

Travere’s pipeline targets specific niches with high unmet needs. Its lead asset, Filspari, benefits from orphan drug designation and fast track status for IgA nephropathy, providing market exclusivity until at least 2031. The company's focus minimizes direct competition and leverages favorable regulatory pathways.

Robust Clinical Pipeline

The company has multiple late-stage candidates, including Filspari (sparsentan), seeking approval for focal segmental glomerulosclerosis (FSGS), and ACCeD for gouty nephropathy. Phase 3 data for FSGS demonstrate positive trends in reducing proteinuria.

Regulatory Progress

In June 2022, the FDA approved Filspari for IgA nephropathy, with similar EMA submissions underway. This regulatory advantage enhances market access and reinforces investor confidence.

Strategic Partnerships and Acquisitions

Post-2021, Travere expanded its pipeline via acquisitions, notably purchasing Retrophin’s assets, which included drugs for rare diseases, strengthening its position in nephrology and hepatology markets.

What Are Travere’s Challenges?

Competitive Landscape

Roche’s Genentech has a dominant presence in nephrology, with established therapies like Rituximab and newer entrants like Calliditas' Nefecon for IgA nephropathy. While Filspari's approval affirms its potential, Roche's pipeline and broader resources pose ongoing competition risks.

Product Launch and Market Penetration

Despite regulatory approval, Travere faces challenges in capturing significant market share for Filspari, given entrenched treatments and the slow adoption curve for new nephrology therapies.

Pricing and Reimbursement

Rare disease drugs often encounter pricing pressures. Filspari’s list price is approximately $70,000 annually, which may limit payer uptake, especially in countries with strict cost controls.

Dependency on a Narrow Pipeline

While focusing on nephrology provides a competitive advantage, it also exposes the company to sector-specific risks, including payor restrictions and clinical trial delays in its pipeline.

What Strategic Moves Could Strengthen Travere?

Expanding the Indication Portfolio

Pursuing new indications for Filspari, including other FSGS subtypes or hypertensive nephropathy, would diversify revenue streams.

Geographic Expansion

Accelerating approvals in Europe, Asia, and emerging markets could boost revenue, especially where nephrology treatment gaps exist.

Partnership Strategy

Forming alliances with larger pharma companies could enhance commercialization capabilities. Collaborations could include co-marketing or licensing agreements, especially for global markets.

Investing in Clinical Development

Advancing pipeline candidates into later stages can reduce dependence on a single product and provide additional market opportunities.

How Does Travere Differ From Peers?

Aspect	Travere	Calliditas	Genentech (Roche)
Focus Area	Rare nephrology diseases	Renal fibrosis, nephropathy	Broad oncology, immune, nephrology
Pipeline Stage	One approved, several in Phase 3	Multiple late-stage assets	Multiple marketed products, pipeline
Market Cap	~$2.6 billion	~$2.4 billion	Over $220 billion
Regulatory Status	Approved for IgA nephropathy, FSGS (pending)	Pending or approved	Multiple approvals, market leader

What Is the Outlook for Travere?

Revenue growth depends on commercial uptake of Filspari, execution in pipeline development, and geographic expansion. The company's valuation reflects high future expectations for multiple pipeline assets. Near-term catalysts include FDA label expansions and emerging trial data.

Key Takeaways

• Travere holds a strategic position in rare nephrology diseases, with a significant approval milestone for Filspari.
• The company’s strengths include a focused pipeline, orphan drug designations, and ongoing regulatory approvals.
• Competition from Roche, Calliditas, and other specialty biotech firms remains stiff, challenging market penetration.
• Expanding indication scope, geographic reach, and pipeline investment are essential to sustain growth.
• Pricing strategies and payor dynamics will influence revenue potential for current and future products.

FAQs

1. What indications does Filspari target?
   IgA nephropathy and FSGS.

2. When did the FDA approve Filspari?
   June 2022.

3. What are the main risks for Travere’s growth?
   Limited pipeline diversification, competitive pressures, and reimbursement hurdles.

4. How does Travere plan to grow geographically?
   Through regulatory submissions in Europe, Asia, and emerging markets, with a focus on nephrology unmet needs.

5. What other products are in Travere's pipeline?
   pipeline candidates include treatments for FSGS and gouty nephropathy, primarily in Phase 2 and Phase 3.

---

References

1. [1] Travere Therapeutics. (2022). Annual Report 2022.
2. [2] FDA. (2022). Approval of Filspari for IgA nephropathy.
3. [3] Roche. (2022). Annual Report 2022.
4. [4] Calliditas Therapeutics. (2022). Corporate Presentation.